474 related articles for article (PubMed ID: 34777560)
1. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
Lu G; Lu Z; Li C; Huang X; Luo Q
Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
[TBL] [Abstract][Full Text] [Related]
2. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
4. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer.
Hou J; Guo C; Lyu G
Colorectal Dis; 2020 May; 22(5):581-587. PubMed ID: 31868956
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
Liu T; Li Y; Song J; Li B; Wang R; Huang T; Qin Y
Cancer Control; 2024; 31():10732748241251562. PubMed ID: 38716503
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
[TBL] [Abstract][Full Text] [Related]
8. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer.
Li J; Liao Y; Ran Y; Wang G; Wu W; Qiu Y; Liu J; Wen N; Jing T; Wang H; Zhang S
BMC Pulm Med; 2020 Oct; 20(1):274. PubMed ID: 33081780
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition.
Lowes LE; Allan AL
Adv Clin Chem; 2018; 83():121-181. PubMed ID: 29304900
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
13. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.
Chebouti I; Kasimir-Bauer S; Buderath P; Wimberger P; Hauch S; Kimmig R; Kuhlmann JD
Oncotarget; 2017 Jul; 8(30):48820-48831. PubMed ID: 28415744
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cell surface vimentin positive circulating tumor cells as a prognostic biomarker for stage III/IV colorectal cancer.
Yu J; Yang M; Peng T; Liu Y; Cao Y
Sci Rep; 2023 Nov; 13(1):18791. PubMed ID: 37914786
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
[TBL] [Abstract][Full Text] [Related]
17. PRL-3 and MMP9 Expression and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells From Patients With Colorectal Cancer: Potential Value in Clinical Practice.
Hong XC; Liang QL; Chen M; Yang HX; Huang J; Yi SL; Wang ZW; Liang HY; Zhang DY; Huang ZY
Front Oncol; 2022; 12():878639. PubMed ID: 35574414
[TBL] [Abstract][Full Text] [Related]
18. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
Jiang S; Mao C; Jiang B; Tan Q; Deng B
Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
[TBL] [Abstract][Full Text] [Related]
19. Associations between the Epithelial-Mesenchymal Transition Phenotypes of Circulating Tumor Cells and the Clinicopathological Features of Patients with Colorectal Cancer.
Wu F; Zhu J; Mao Y; Li X; Hu B; Zhang D
Dis Markers; 2017; 2017():9474532. PubMed ID: 29430076
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
